Supernus Pharmaceuticals develops and commercializes treatments for central nervous system diseases. Company news centers on its neuroscience portfolio, including approved treatments for attention-deficit hyperactivity disorder, Parkinson's disease-related dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Recurring updates cover product revenue trends for Qelbree, GOCOVRI, ZURZUVAE, ONAPGO and other CNS therapies, quarterly financial results, collaboration and licensing revenue, investor conference participation, and pipeline activity for novel CNS product candidates such as SPN-820 in major depressive disorder.
Supernus Pharmaceuticals (Nasdaq: SUPN) expects to report third quarter 2025 financial and business results after market close on Tuesday, November 4, 2025. Management will host a conference call and webcast the same day at 4:30 p.m. ET with Jack Khattar, President and CEO, and Tim Dec, SVP and CFO, presenting prepared remarks followed by a Q&A session.
A live webcast will be available in the Events & Presentations section of the investor relations site at www.supernus.com/investors. Participants may pre-register to receive a dial-in number and personalized conference code; dial-in is recommended 15 minutes before the start. A replay will be posted on the investor site and remain available for 60 days after the live call.
Supernus Pharmaceuticals (Nasdaq: SUPN), a CNS-focused biopharmaceutical company, has announced its participation in three major investor conferences in September 2025. Management will attend the Cantor Global Healthcare Conference on September 3, the Wells Fargo Healthcare Conference on September 4, and TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 18.
The company will participate in fireside chats at each event, with presentations scheduled for 8:00 a.m. ET, 8:45 a.m. ET, and 10:40 a.m. ET respectively. Live audio webcasts will be available on the company's website, with replays accessible for 60 days following each conference.
Supernus Pharmaceuticals (Nasdaq: SUPN) reported Q2 2025 financial results, highlighting strong performance in key products. Total revenues reached $165.5 million in Q2 2025, with flagship product Qelbree® achieving 31% growth to $77.6 million and GOCOVRI® growing 16% to $36.7 million.
The company completed the strategic acquisition of Sage Therapeutics on July 31, 2025, strengthening its CNS portfolio with ZURZUVAE®. Notable developments include the successful launch of ONAPGO™ in April 2025, with over 750 enrollment forms from 300+ prescribers. The company increased its 2025 revenue guidance to $670-$700 million, reflecting strong H1 performance and the Sage acquisition impact.
Supernus Pharmaceuticals (Nasdaq: SUPN) has completed its acquisition of Sage Therapeutics, strengthening its position in neuropsychiatric treatments. The deal includes ZURZUVAE®, the first FDA-approved oral medicine for postpartum depression, and a CNS discovery platform.
The transaction structure includes $8.50 per share in cash plus contingent value rights (CVRs) worth up to $3.50 per share tied to specific milestones. The acquisition garnered 58% shareholder approval with 36,313,509 shares tendered. Supernus expects annual cost synergies of up to $200 million and projects the acquisition to be accretive by 2026.
The deal adds collaboration revenue from ZURZUVAE (50% of U.S. net sales through Biogen partnership) and complements Supernus' existing portfolio including Qelbree®, ONAPGO™, and GOCOVRI®.
Supernus Pharmaceuticals (NASDAQ: SUPN) announced the expiration of the Hart-Scott-Rodino waiting period for its proposed acquisition of Sage Therapeutics (NASDAQ: SAGE). The tender offer includes a cash payment of $8.50 per share plus one non-transferable contingent value right (CVR) worth up to $3.50 per share based on milestone achievements.
The CVR milestones include: $0.50 for ZURZUVAE's first commercial sale in Japan by June 2026, $1.00 for U.S. sales exceeding $250M by 2027, $1.00 for U.S. sales over $300M by 2028, and $1.00 for U.S. sales surpassing $375M by 2030. The tender offer expires on July 30, 2025, after which Supernus plans to complete the acquisition through a merger, making Sage its wholly owned subsidiary.
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET on the same day, featuring CEO Jack Khattar and CFO Tim Dec. The presentation will be available via webcast through the company's investor relations website, with a replay accessible for 60 days following the event.
Supernus Pharmaceuticals (NASDAQ: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, announced its participation in the 2025 Jefferies Global Healthcare Conference. President and CEO Jack A. Khattar will engage in a fireside chat on June 4, 2025, at 2:00 p.m. ET in New York City.
Investors can arrange meetings with management through the Jefferies conference coordinator. The presentation will be available via live audio webcast, accessible through the company's website, with a replay available for 60 days post-conference.
Supernus Pharmaceuticals (SUPN) has received Paragraph IV Notice Letters regarding Abbreviated New Drug Applications (ANDAs) from third parties for its drug Qelbree (viloxazine extended-release capsules) in 100, 150, and 200 mg base formulations. The company plans to vigorously defend its intellectual property rights for Qelbree, which is protected by six U.S. patents listed in the FDA's Orange Book. Three patents expire in September 2029, two in February 2033, and one in April 2035.